McGovern Karen

Infinity Pharmaceuticals, Inc., Cambridge, MA, United States of America.

Show Academic Trajectory

Ego Network

D-Core

Research Interests

Author Statistics

Experience

Education

Bio

None

Papers36 papers

Sort

By YearBy Citation

Abstract 2474: Potent small molecule TEAD inhibitors targeting the Hippo pathway exhibit antiproliferation in vitro and anti-tumor effect in vivo

Ben Amidon, Sakeena Syed, Jill Cavanaugh, Hyejin Frosch, Prabitha Natarajan, Jeffrey Ecsedy,Karen McGovern, Alfredo C. Castro

Cancer Research, (2020): 2474-2474

Bibtex

Abstract PR05: Blockade of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression

Luis F. Campesato,Sadna Budhu, Mathieu Gigoux,Jeremy Tchaicha, Stephane Pourpe,Cailian Liu,Dmitriy Zamarin,Mark G. Manfredi,Karen McGovern,Jedd D. Wolchok,Taha Merghoub

Cancer immunology research, (2020)

Bibtex

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

Luis Felipe Campesato,Sadna Budhu,Jeremy Tchaicha, Chien-Huan Weng, Mathieu Gigoux, Ivan Jose Cohen,David Redmond, Levi Mangarin, Stephane Pourpe,Cailian Liu,Roberta Zappasodi,Dmitriy Zamarin

Nature communications, no. 1 (2020): 4011

WOSBibtex

Abstract 4131: Overcoming aryl hydrocarbon receptor mediated tumor immunosuppression

Jeremy Tchaicha, Silvia Coma, Meghan Walsh, Jill Cavanaugh, Marta Sanchez-Martin, X. Michelle Zhang, Alfredo Castro, Jeff Ecsedy,Mark Manfredi,Karen McGovern

Immunology, (2019)

Bibtex

Abstract B008: Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition

Silvia Coma, Jillian Cavanaugh, James Nolan,Jeremy Tchaicha,Karen McGovern,Everett Stone,John Blazeck,Candice Lamb,George Georgiou,Mark G Manfredi, Michelle Zhang

Cancer immunology research, (2019)

Bibtex

Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

Todd A Triplett, Kendra C Garrison, Nicholas Marshall,Moses Donkor, John Blazeck,Candice Lamb, Ahlam Qerqez, Joseph D Dekker, Yuri Tanno, Wei-Cheng Lu, Christos S Karamitros, Kyle Ford

Nature biotechnology, (2018)

Cited by7WOSBibtex

Abstract 4723: Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor

Jeremy H. Tchaicha,Karen McGovern, Luis Felipe Campesato, Silvia Coma, Xiaoyan Michelle Zhang, Meghan Walsh, Jill Cavanaugh,Taha Merghoub,Jedd D. Wolchok,Mark Manfredi

Cancer Research, (2018): 4723-4723

Bibtex

Abstract 3757: Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine

Silvia Coma, Jill Cavanaugh, Jim Nolan,Jeremy H. Tchaicha,Karen McGovern,Everett M. Stone,Candice Lamb, Christos Karamitros, John Blazek, Kendra Garrison,George Georgiou,Mark Manfredi

Cancer Research, (2018): 3757-3757

Bibtex

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

Kerrie Faia,Kerry White,Erin Murphy,Jennifer Proctor,Melissa Pink, Nicole Kosmider,Karen McGovern,Jeffery Kutok

PloS one, no. 8 (2018)

Cited by1WOSBibtex

The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation

Honyin Chiu,Sharmila Mallya, Phuongthao Nguyen, Annie Mai, Leandra V Jackson,David G Winkler, Jonathan P DiNitto,Erin E Brophy,Karen McGovern,Jeffery L Kutok,David A Fruman

Frontiers in immunology, (2017): 747

Cited by5WOSBibtex

Abstract 554: Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models

Olivier De Henau,Taha Merghoub,David W. Winkler,Sujata Sharma,Melissa Pink,Jeremy H. Tchaicha,Matthew P. Rausch,Jennifer L. Proctor, Nicole Kosmider,John Soglia,Vito J. Palombella,Jeffery L. Kutok

Cancer Research, (2016): 554-554

Bibtex

Abstract B029: The potent and selective phosphoinositide-3-kinase-gamma inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment

Jeffery L. Kutok,Janid A. Ali, Erin Brophy, Alfredo C. Castro, Jonathan P. DiNitto, Catherine A. Evans, Kerrie Faia, Stanley Goldstein, Nicole Kosmider, Andre Lescarbeau, Tao Liu, Christian Martin

Cancer immunology research, (2016)

Bibtex

PI3Kγ is a molecular switch that controls immune suppression

Megan M Kaneda,Karen S Messer,Natacha Ralainirina,Hongying Li, Christopher J Leem, Sara Gorjestani, Gyunghwi Woo, Abraham V Nguyen, Camila C Figueiredo,Philippe Foubert,Michael C Schmid,Melissa Pink

Nature, (2016)

Cited by136WOSNATUREBibtex

Corrigendum: PI3Kγ is a molecular switch that controls immune suppression

Megan M. Kaneda,Karen S. Messer, Natacha Ralainirina, Hongying Li, Christopher J. Leem, Sara Gorjestani, Gyunghwi Woo, Abraham V. Nguyen, Camila C. Figueiredo,Philippe Foubert,Michael C. Schmid,Melissa Pink

Nature, (2016)

Cited by2WOSNATUREBibtex

Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment